GENimmune NV

GENimmune is a biopharmaceutical company developing immune therapeutics to cure and prevent human disease by optimizing the immune response. The new company intends to become a key player in the treatment of major, intractable diseases by the creation of a broad and effective pipeline of modern immune therapeutics and vaccines. It will do so by synergizing its technical and clinical expertise for in-house product development, co-development projects, and biomanufacturing partnerships. GENimmune is currently developing novel therapeutic vaccines and monoclonal antibodies against chronic diseases caused by the hepatitis B and hepatitis C viruses, as well as against human papillomavirus, the cause of cervical cancer. GENimmune is a wholly owned subsidiary of Innogenetics NV.